Related Experiment Video
Updated: Jun 29, 2025
Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
Published on: March 29, 2018
BMP2-ERK-ATF4 Axis-Based 6-methoxybenzofuran Compound I-9 Acts as Candidate Drug for Bone Formation and
Ziying Zhou1, Chenxi Zhao1, Siyan Li1
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Abstract:
As the global population ages, the number of patients with osteoporosis is rapidly rising. The existing first-line clinical drugs are bone resorption inhibitors that have difficulty restoring the bone mass of elderly patients to the safe range. The range and period of use of existing peptides and monoclonal antibodies are limited, and small-molecule bone formation-promoting drugs are urgently required. We established an I-9 synthesis route with high yield, simple operation, and low cost that was suitable for future large-scale production. I-9 administration promoted bone formation and increased bone mass in mice with low bone mass in an aged C57 mouse model. Our findings revealed a hitherto undescribed pathway involving the BMP2-ERK-ATF4 axis that promotes osteoblast differentiation; I-9 has favorable biosafety in mice. This study systematically investigated the efficacy, safety, and mechanism of I-9 for treating osteoporosis and positions this drug for preclinical research in the future. Thus, this study has promoted the development of small-molecule bone-promoting drugs.
Insights
A novel small molecule, I-9, effectively promotes bone formation and increases bone mass in aged mice. This osteoporosis drug candidate works through a newly discovered BMP2-ERK-ATF4 pathway, showing promise for future treatments.
Area of Science:
- Pharmacology
- Bone Biology
- Drug Discovery
Background:
- Osteoporosis prevalence is increasing globally due to population aging.
- Current treatments like bone resorption inhibitors have limitations in restoring bone mass in elderly patients.
- Existing peptide and antibody therapies have restricted usage, highlighting the need for novel small-molecule bone formation agents.
Purpose of the Study:
- To develop and evaluate a novel small-molecule drug, I-9, for osteoporosis treatment.
- To investigate the efficacy, safety, and underlying mechanism of I-9 in promoting bone formation.
- To establish a scalable synthesis route for I-9 suitable for large-scale production.
Main Methods:
- Development of a high-yield, cost-effective synthesis route for I-9.
- Administration of I-9 to an aged C57 mouse model with low bone mass.
- Investigation of the molecular mechanism involving the BMP2-ERK-ATF4 signaling pathway.
- Assessment of I-9 biosafety in mice.
Main Results:
- The developed synthesis route for I-9 is efficient, simple, and cost-effective.
- I-9 administration significantly promoted bone formation and increased bone mass in aged mice.
- A novel osteogenic pathway, BMP2-ERK-ATF4, was identified as crucial for I-9's mechanism of action.
- I-9 demonstrated favorable biosafety profiles in the tested mouse model.
Conclusions:
- I-9 is a promising small-molecule drug candidate for osteoporosis treatment.
- The study elucidated a novel BMP2-ERK-ATF4 pathway that promotes osteoblast differentiation.
- I-9's efficacy and safety profile position it for further preclinical development.
- This research advances the development of effective small-molecule bone-promoting drugs.
More Related Videos
00:12A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput
Published on: September 22, 2019
07:53Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
Published on: December 10, 2010
